Cargando…

The clinical benefit of instituting a prospective clinical community-acquired respiratory virus surveillance program in allogeneic hematopoietic stem cell transplantation

BACKGROUND: There is a lack of studies comparing clinical outcomes among retrospective versus prospective cohorts of allogeneic stem cell transplant (allo-HCT) recipients with community acquired respiratory virus (CARV) infections. METHODS: We compare outcomes in two consecutive cohorts of allo-HCT...

Descripción completa

Detalles Bibliográficos
Autores principales: Piñana, JoséLuis, Montoro, Juan, Aznar, Carla, Lorenzo, Ignacio, Gómez, María Dolores, Guerreiro, Manuel, Carretero, Carlos, González-Barberá, Eva María, Balaguer-Roselló, Aitana, Sanz, Rosa, Salavert, Miguel, Navarro, David, Sanz, Miguel A., Sanz, Guillermo, Sanz, Jaime
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The British Infection Association. Published by Elsevier Ltd. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7112613/
https://www.ncbi.nlm.nih.gov/pubmed/31972212
http://dx.doi.org/10.1016/j.jinf.2019.12.022
_version_ 1783513507177693184
author Piñana, JoséLuis
Montoro, Juan
Aznar, Carla
Lorenzo, Ignacio
Gómez, María Dolores
Guerreiro, Manuel
Carretero, Carlos
González-Barberá, Eva María
Balaguer-Roselló, Aitana
Sanz, Rosa
Salavert, Miguel
Navarro, David
Sanz, Miguel A.
Sanz, Guillermo
Sanz, Jaime
author_facet Piñana, JoséLuis
Montoro, Juan
Aznar, Carla
Lorenzo, Ignacio
Gómez, María Dolores
Guerreiro, Manuel
Carretero, Carlos
González-Barberá, Eva María
Balaguer-Roselló, Aitana
Sanz, Rosa
Salavert, Miguel
Navarro, David
Sanz, Miguel A.
Sanz, Guillermo
Sanz, Jaime
author_sort Piñana, JoséLuis
collection PubMed
description BACKGROUND: There is a lack of studies comparing clinical outcomes among retrospective versus prospective cohorts of allogeneic stem cell transplant (allo-HCT) recipients with community acquired respiratory virus (CARV) infections. METHODS: We compare outcomes in two consecutive cohorts of allo-HCT recipients with CARV infections. The retrospective cohort included 63 allo-HCT recipients with 108 CARV infections from January 2013 to April 2016 who were screened and managed following standard clinical practice based on influenza and respiratory syncytial virus rapid antigen detection methods. The prospective cohort was comprised of 144 consecutive recipients with 297 CARV episodes included in a prospective interventional clinical surveillance program (ProClinCarvSur-P) based on syndromic multiplex PCR as first-line test from May 2016 to December 2018 at a single transplant center. RESULTS: CARV infections in the retrospective cohort showed more severe clinical features at the time of diagnosis compared to the prospective cohort (fever 83% vs. 57%, hospital admission 69% vs. 28% and lower respiratory tract 58% vs. 31%, respectively, p ≤ 0.002 for all comparisons). Antiviral therapy was more commonly prescribed in the prospective cohort (69 vs. 43 treated CARV episodes), particularly at the upper respiratory tract disease stage (34 vs. 12 treated CARV episodes). Three-month all-cause mortality was significantly higher in the retrospective cohort (n = 23, 37% vs. n = 10, 7%, p < 0.0001). Multivariate logistic regression analysis showed that recipients included in ProClinCarvSur-P had lower mortality rate [odds ratio 0.31, 95% confidence interval 0.12–0.7, p = 0.01]. CONCLUSION: This study report on outcome differences when reporting retrospective vs. prospective CARV infections after allo-HCT. Recipients included in a ProClinCarvSur-P had lower mortality.
format Online
Article
Text
id pubmed-7112613
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The British Infection Association. Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-71126132020-04-02 The clinical benefit of instituting a prospective clinical community-acquired respiratory virus surveillance program in allogeneic hematopoietic stem cell transplantation Piñana, JoséLuis Montoro, Juan Aznar, Carla Lorenzo, Ignacio Gómez, María Dolores Guerreiro, Manuel Carretero, Carlos González-Barberá, Eva María Balaguer-Roselló, Aitana Sanz, Rosa Salavert, Miguel Navarro, David Sanz, Miguel A. Sanz, Guillermo Sanz, Jaime J Infect Article BACKGROUND: There is a lack of studies comparing clinical outcomes among retrospective versus prospective cohorts of allogeneic stem cell transplant (allo-HCT) recipients with community acquired respiratory virus (CARV) infections. METHODS: We compare outcomes in two consecutive cohorts of allo-HCT recipients with CARV infections. The retrospective cohort included 63 allo-HCT recipients with 108 CARV infections from January 2013 to April 2016 who were screened and managed following standard clinical practice based on influenza and respiratory syncytial virus rapid antigen detection methods. The prospective cohort was comprised of 144 consecutive recipients with 297 CARV episodes included in a prospective interventional clinical surveillance program (ProClinCarvSur-P) based on syndromic multiplex PCR as first-line test from May 2016 to December 2018 at a single transplant center. RESULTS: CARV infections in the retrospective cohort showed more severe clinical features at the time of diagnosis compared to the prospective cohort (fever 83% vs. 57%, hospital admission 69% vs. 28% and lower respiratory tract 58% vs. 31%, respectively, p ≤ 0.002 for all comparisons). Antiviral therapy was more commonly prescribed in the prospective cohort (69 vs. 43 treated CARV episodes), particularly at the upper respiratory tract disease stage (34 vs. 12 treated CARV episodes). Three-month all-cause mortality was significantly higher in the retrospective cohort (n = 23, 37% vs. n = 10, 7%, p < 0.0001). Multivariate logistic regression analysis showed that recipients included in ProClinCarvSur-P had lower mortality rate [odds ratio 0.31, 95% confidence interval 0.12–0.7, p = 0.01]. CONCLUSION: This study report on outcome differences when reporting retrospective vs. prospective CARV infections after allo-HCT. Recipients included in a ProClinCarvSur-P had lower mortality. The British Infection Association. Published by Elsevier Ltd. 2020-03 2020-01-20 /pmc/articles/PMC7112613/ /pubmed/31972212 http://dx.doi.org/10.1016/j.jinf.2019.12.022 Text en © 2020 The British Infection Association. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Piñana, JoséLuis
Montoro, Juan
Aznar, Carla
Lorenzo, Ignacio
Gómez, María Dolores
Guerreiro, Manuel
Carretero, Carlos
González-Barberá, Eva María
Balaguer-Roselló, Aitana
Sanz, Rosa
Salavert, Miguel
Navarro, David
Sanz, Miguel A.
Sanz, Guillermo
Sanz, Jaime
The clinical benefit of instituting a prospective clinical community-acquired respiratory virus surveillance program in allogeneic hematopoietic stem cell transplantation
title The clinical benefit of instituting a prospective clinical community-acquired respiratory virus surveillance program in allogeneic hematopoietic stem cell transplantation
title_full The clinical benefit of instituting a prospective clinical community-acquired respiratory virus surveillance program in allogeneic hematopoietic stem cell transplantation
title_fullStr The clinical benefit of instituting a prospective clinical community-acquired respiratory virus surveillance program in allogeneic hematopoietic stem cell transplantation
title_full_unstemmed The clinical benefit of instituting a prospective clinical community-acquired respiratory virus surveillance program in allogeneic hematopoietic stem cell transplantation
title_short The clinical benefit of instituting a prospective clinical community-acquired respiratory virus surveillance program in allogeneic hematopoietic stem cell transplantation
title_sort clinical benefit of instituting a prospective clinical community-acquired respiratory virus surveillance program in allogeneic hematopoietic stem cell transplantation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7112613/
https://www.ncbi.nlm.nih.gov/pubmed/31972212
http://dx.doi.org/10.1016/j.jinf.2019.12.022
work_keys_str_mv AT pinanajoseluis theclinicalbenefitofinstitutingaprospectiveclinicalcommunityacquiredrespiratoryvirussurveillanceprograminallogeneichematopoieticstemcelltransplantation
AT montorojuan theclinicalbenefitofinstitutingaprospectiveclinicalcommunityacquiredrespiratoryvirussurveillanceprograminallogeneichematopoieticstemcelltransplantation
AT aznarcarla theclinicalbenefitofinstitutingaprospectiveclinicalcommunityacquiredrespiratoryvirussurveillanceprograminallogeneichematopoieticstemcelltransplantation
AT lorenzoignacio theclinicalbenefitofinstitutingaprospectiveclinicalcommunityacquiredrespiratoryvirussurveillanceprograminallogeneichematopoieticstemcelltransplantation
AT gomezmariadolores theclinicalbenefitofinstitutingaprospectiveclinicalcommunityacquiredrespiratoryvirussurveillanceprograminallogeneichematopoieticstemcelltransplantation
AT guerreiromanuel theclinicalbenefitofinstitutingaprospectiveclinicalcommunityacquiredrespiratoryvirussurveillanceprograminallogeneichematopoieticstemcelltransplantation
AT carreterocarlos theclinicalbenefitofinstitutingaprospectiveclinicalcommunityacquiredrespiratoryvirussurveillanceprograminallogeneichematopoieticstemcelltransplantation
AT gonzalezbarberaevamaria theclinicalbenefitofinstitutingaprospectiveclinicalcommunityacquiredrespiratoryvirussurveillanceprograminallogeneichematopoieticstemcelltransplantation
AT balaguerroselloaitana theclinicalbenefitofinstitutingaprospectiveclinicalcommunityacquiredrespiratoryvirussurveillanceprograminallogeneichematopoieticstemcelltransplantation
AT sanzrosa theclinicalbenefitofinstitutingaprospectiveclinicalcommunityacquiredrespiratoryvirussurveillanceprograminallogeneichematopoieticstemcelltransplantation
AT salavertmiguel theclinicalbenefitofinstitutingaprospectiveclinicalcommunityacquiredrespiratoryvirussurveillanceprograminallogeneichematopoieticstemcelltransplantation
AT navarrodavid theclinicalbenefitofinstitutingaprospectiveclinicalcommunityacquiredrespiratoryvirussurveillanceprograminallogeneichematopoieticstemcelltransplantation
AT sanzmiguela theclinicalbenefitofinstitutingaprospectiveclinicalcommunityacquiredrespiratoryvirussurveillanceprograminallogeneichematopoieticstemcelltransplantation
AT sanzguillermo theclinicalbenefitofinstitutingaprospectiveclinicalcommunityacquiredrespiratoryvirussurveillanceprograminallogeneichematopoieticstemcelltransplantation
AT sanzjaime theclinicalbenefitofinstitutingaprospectiveclinicalcommunityacquiredrespiratoryvirussurveillanceprograminallogeneichematopoieticstemcelltransplantation
AT pinanajoseluis clinicalbenefitofinstitutingaprospectiveclinicalcommunityacquiredrespiratoryvirussurveillanceprograminallogeneichematopoieticstemcelltransplantation
AT montorojuan clinicalbenefitofinstitutingaprospectiveclinicalcommunityacquiredrespiratoryvirussurveillanceprograminallogeneichematopoieticstemcelltransplantation
AT aznarcarla clinicalbenefitofinstitutingaprospectiveclinicalcommunityacquiredrespiratoryvirussurveillanceprograminallogeneichematopoieticstemcelltransplantation
AT lorenzoignacio clinicalbenefitofinstitutingaprospectiveclinicalcommunityacquiredrespiratoryvirussurveillanceprograminallogeneichematopoieticstemcelltransplantation
AT gomezmariadolores clinicalbenefitofinstitutingaprospectiveclinicalcommunityacquiredrespiratoryvirussurveillanceprograminallogeneichematopoieticstemcelltransplantation
AT guerreiromanuel clinicalbenefitofinstitutingaprospectiveclinicalcommunityacquiredrespiratoryvirussurveillanceprograminallogeneichematopoieticstemcelltransplantation
AT carreterocarlos clinicalbenefitofinstitutingaprospectiveclinicalcommunityacquiredrespiratoryvirussurveillanceprograminallogeneichematopoieticstemcelltransplantation
AT gonzalezbarberaevamaria clinicalbenefitofinstitutingaprospectiveclinicalcommunityacquiredrespiratoryvirussurveillanceprograminallogeneichematopoieticstemcelltransplantation
AT balaguerroselloaitana clinicalbenefitofinstitutingaprospectiveclinicalcommunityacquiredrespiratoryvirussurveillanceprograminallogeneichematopoieticstemcelltransplantation
AT sanzrosa clinicalbenefitofinstitutingaprospectiveclinicalcommunityacquiredrespiratoryvirussurveillanceprograminallogeneichematopoieticstemcelltransplantation
AT salavertmiguel clinicalbenefitofinstitutingaprospectiveclinicalcommunityacquiredrespiratoryvirussurveillanceprograminallogeneichematopoieticstemcelltransplantation
AT navarrodavid clinicalbenefitofinstitutingaprospectiveclinicalcommunityacquiredrespiratoryvirussurveillanceprograminallogeneichematopoieticstemcelltransplantation
AT sanzmiguela clinicalbenefitofinstitutingaprospectiveclinicalcommunityacquiredrespiratoryvirussurveillanceprograminallogeneichematopoieticstemcelltransplantation
AT sanzguillermo clinicalbenefitofinstitutingaprospectiveclinicalcommunityacquiredrespiratoryvirussurveillanceprograminallogeneichematopoieticstemcelltransplantation
AT sanzjaime clinicalbenefitofinstitutingaprospectiveclinicalcommunityacquiredrespiratoryvirussurveillanceprograminallogeneichematopoieticstemcelltransplantation